Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. Mai 2026 07:00 ET | Quelle: Vanotech Ltd

Kanghong Pharmaceutical and Vanotech Announce Positive Phase 2b Results for KH607 in Major Depressive Disorder

CHENGDU, China and ROCKAWAY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Kanghong Pharmaceutical and Vanotech Ltd. today announced the successful completion of a Phase 2b clinical trial evaluating KH607...
13. Mai 2026 14:09 ET | Quelle: Vanotech Ltd

Chengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations

CHENGDU, China and ROCKAWAY, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Chengdu Origen Biotechnology Co., Ltd. (“Chengdu Origen”) and Vanotech Ltd. (“Vanotech”) announced today that the US FDA granted...
02. Mai 2025 04:59 ET | Quelle: Vanotech Ltd

Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2401 Phase 1 Trial of Gene Therapy for Wet Age-Related Macular Degeneration

Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2401 Phase 1 Trial of Gene Therapy for Wet Age-Related Macular Degeneration
13. März 2025 07:00 ET | Quelle: Vanotech Ltd

Vanotech Appoints Matthew Schiller to Lead Business Development

Vanoteh Ltd. appoints Matthew Schiller to head business development